Non-small Cell Lung Cancer (NSCLC) in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Explore the Non-Small Cell Lung Cancer (NSCLC) therapeutics market across the 7MM with forecasts to 2032. Analyze epidemiology trends, pipeline drugs, immunotherapies, targeted therapies, market growth, competitive landscape, clinical development, and future opportunities shaping the global NSCLC treatment
Report Value Proposition – Why This Matters for You
The Non-Small Cell Lung Cancer (NSCLC) therapeutics market across the seven major markets (7MM) was valued at $24.1 billion in 2022 and is forecast to reach $56.5 billion by 2032, reflecting a CAGR of 8.9% during the forecast period.
This report helps stakeholders understand how advances in immunotherapy, targeted therapies, precision medicine, and pipeline innovation are transforming the treatment landscape for NSCLC. It provides comprehensive analysis of disease epidemiology, patient populations, treatment patterns, competitive dynamics, and future market opportunities.
Supported by GlobalData’s healthcare intelligence, forecasting models, and analyst expertise, the report offers actionable insight into marketed therapies, late-stage pipeline products, clinical development activity, and emerging treatment strategies shaping the future of NSCLC care.

Key Insights in the NSCLC Therapeutics Market
- The NSCLC therapeutics market across the 7MM was valued at $24.1 billion in 2022.
- The market is forecast to reach $56.5 billion by 2032.
- More than 40 pipeline therapies are expected to enter the market during the forecast period.
- Diagnosed incident NSCLC cases across the 7MM are expected to increase from 514,561 in 2022 to 564,314 by 2032.
- Immune checkpoint inhibitors continue to drive significant market growth.
- Precision medicine approaches are expanding through biomarker-driven targeted therapies.
- Label expansion of currently marketed therapies into earlier treatment settings is expected to support future growth.
- Second- and third-line treatment settings are forecast to experience strong expansion due to the introduction of differentiated therapies.
- Biosimilar competition and generic erosion are expected to increase pricing pressure toward the end of the forecast period.
- Loss of exclusivity for leading therapies such as Tagrisso and Alecensa may impact future market dynamics.
Scope
What You Will Learn
- NSCLC epidemiology trends and patient population forecasts through 2032
- Market size forecasts across the seven major pharmaceutical markets (7MM)
- Current treatment landscape and standard-of-care evolution
- Immunotherapy and immune checkpoint inhibitor market developments
- Precision medicine and targeted therapy opportunities
- Pipeline analysis of emerging Phase III and Phase IIb therapies
- Clinical trial activity and innovation trends
- Market drivers, barriers, and competitive dynamics
- Revenue forecasts, therapy utilization, and treatment adoption patterns
- Strategic opportunities for pharmaceutical companies and investors
Target Buyers for This Report
This report may support decision-making for:
- Pharmaceutical and biotechnology companies
- Oncology and precision medicine teams
- Business development and licensing professionals
- Healthcare investors and private equity firms
- Clinical development and R&D organizations
- Commercial strategy and market access teams
- Competitive intelligence professionals
- Healthcare consulting firms
- Oncology-focused market research teams
- Regulatory and policy specialists
How Companies Use This Report
Pharmaceutical companies may use this report to assess future commercial opportunities, evaluate pipeline competition, and identify strategic areas for investment within the NSCLC treatment landscape.
Oncology-focused biotech firms can leverage the analysis to understand evolving treatment paradigms, emerging therapeutic modalities, and unmet patient needs across major global markets.
Business development teams may use the report to identify licensing opportunities, evaluate competitive positioning, and assess the commercial potential of late-stage pipeline assets.
Investors and strategic planners can also use the insights to evaluate market growth potential, innovation trends, and long-term revenue opportunities within the global NSCLC therapeutics sector.
Key Highlights
This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan).
The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.
Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the NSCLC market.
The base year of the sales forecast model is 2022, and the forecast period is 2022-2032.
Reasons to Buy
Merck
Johnson and Johnson
Roche
Takeda
Xcovery Holdings
Pfizer
Novartis
Daiichi Sankyo
Murus
Array BioPharma
GSK
Bristol-Myers Squibb
Boehringer Ingelheim
Janssen
Eli Lylly
Genmab
Astellas
Mirati Therapeutics
Amgen
WuXi Advanced Therapies
Regeneron
Sanofi
BeiGene
Blueprint Medicines
Bayer
Nuvalent
AbbVie
Gilead Sciences
BionTech
Akeso
Summit Therapeutics
Iovance Biotherapeutics
OncoC4
Arrivent Biopharma
Dizal Pharmaceutical
Taiho Oncology
Shanghai Hengrui Pharmaceuticals
ImmunityBio
Immutep
Revolution Medicines
HUTCHMED (Suzhou)
Innate Pharma
Arcus Biosciences
Guangzhou gloria Biosciences
Incyte
Nuvation Bio
iTeos Therapeutics
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports

